Source: BioPharma-Reporter

IvexSol: Solving CAR-T's viral vector problem: Cellares and iVexSol team up to streamline manufacturing

San Francisco based Cellares is partnering with Lexington, Massachusetts headquartered iVexSol to accelerate and improve the quality of viral vector manufacturing and transduction.

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Rodney L Rietze's photo - Co-Founder & CEO of IvexSol

Co-Founder & CEO

Rodney L Rietze

CEO Approval Rating

90/100

Read more